Literature DB >> 23294178

Cyclodextrin-mediated enhancement of riboflavin solubility and corneal permeability.

Peter W J Morrison1, Che J Connon, Vitaliy V Khutoryanskiy.   

Abstract

Cyclodextrins are water-soluble cyclic oligosaccharides consisting of six, seven, and eight α-(1,4)-linked glucopyranose subunits. This study reports the use of different cyclodextrins in eye drop formulations to improve the aqueous solubility and corneal permeability of riboflavin. Riboflavin is a poorly soluble drug with a solubility up to 0.08 mg mL(-1) in deionized water. It is used as a drug topically administered to the eye to mediate UV-induced corneal cross-linking in the treatment of keratoconus. Aqueous solutions of β-cyclodextrin (10-30 mg mL(-1)) can enhance the solubility of riboflavin up to 0.12-0.19 mg mL(-1), whereas the higher concentration of α-cyclodextrin (100 mg mL(-1)) achieved a lower level of enhancement of 0.11 mg mL(-1). The other oligosaccharides were found to be inefficient for this purpose. In vitro diffusion experiments performed with fresh and cryopreserved bovine cornea have demonstrated that β-cyclodextrin enhances riboflavin permeability. The mechanism of this enhancement was examined through microscopic histological analysis of the cornea and is discussed in this paper.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23294178     DOI: 10.1021/mp3005963

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  17 in total

Review 1.  In vitro and ex vivo corneal penetration and absorption models.

Authors:  Priyanka Agarwal; Ilva D Rupenthal
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

2.  Taste perception of cyclic oligosaccharides: α, β, and γ cyclodextrins.

Authors:  Laura E Martin; Juyun Lim
Journal:  Chem Senses       Date:  2022-01-01       Impact factor: 3.160

3.  The Effect of Sodium Iodide on Stromal Loading, Distribution and Degradation of Riboflavin in a Rabbit Model of Transepithelial Corneal Crosslinking.

Authors:  Roy S Rubinfeld; Glenwood G Gum; Jonathan H Talamo; Edward C Parsons
Journal:  Clin Ophthalmol       Date:  2021-05-11

Review 4.  Peptidomimetics Therapeutics for Retinal Disease.

Authors:  Dylan E Parsons; Soo Hyeon Lee; Young Joo Sun; Gabriel Velez; Alexander G Bassuk; Mark Smith; Vinit B Mahajan
Journal:  Biomolecules       Date:  2021-02-24

5.  Enhancement in corneal permeability of riboflavin using calcium sequestering compounds.

Authors:  Peter W J Morrison; Vitaliy V Khutoryanskiy
Journal:  Int J Pharm       Date:  2014-06-10       Impact factor: 5.875

6.  Voriconazole Composited Polyvinyl Alcohol/Hydroxypropyl-β-Cyclodextrin Nanofibers for Ophthalmic Delivery.

Authors:  Xiaoyi Sun; Zhenwei Yu; Zhengyuan Cai; Lingyan Yu; Yuanyuan Lv
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

7.  Bio-Distribution and Pharmacokinetics of Topically Administered γ-Cyclodextrin Based Eye Drops in Rabbits.

Authors:  Martin Kallab; Kornelia Schuetzenberger; Nikolaus Hommer; Bhavapriya Jasmin Schäfer; Doreen Schmidl; Helga Bergmeister; Markus Zeitlinger; Aimin Tan; Phatsawee Jansook; Thorsteinn Loftsson; Einar Stefansson; Gerhard Garhöfer
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-18

8.  Corneal absorption of a new riboflavin-nanostructured system for transepithelial collagen cross-linking.

Authors:  Katia M Bottos; Anselmo G Oliveira; Patrícia A Bersanetti; Regina F Nogueira; Acácio A S Lima-Filho; José A Cardillo; Paulo Schor; Wallace Chamon
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

9.  Novel lutein loaded lipid nanoparticles on porcine corneal distribution.

Authors:  Chi-Hsien Liu; Hao-Che Chiu; Wei-Chi Wu; Soubhagya Laxmi Sahoo; Ching-Yun Hsu
Journal:  J Ophthalmol       Date:  2014-07-02       Impact factor: 1.909

Review 10.  Theoretical basis, laboratory evidence, and clinical research of chemical surgery of the cornea: cross-linking.

Authors:  Amanda C da Paz; Patrícia A Bersanetti; Marcella Q Salomão; Renato Ambrósio; Paulo Schor
Journal:  J Ophthalmol       Date:  2014-08-18       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.